SHANGHAI, March 31, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011), has been granted Orphan...
Hence then, the article about abbisko therapeutics fgfr4 inhibitor irpagratinib granted orphan drug designation by ema for hepatocellular carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma )
Also on site :
- Sony’s Indian Version of ‘Who Wants to Be a Millionaire?’ Hosted by Amitabh Bachchan, Adds Google Gemini as AI Guide (EXCLUSIVE)
- ‘Naruto’ Movie Launches Global Casting Search to Find Actors to Play Live-Action Naruto, Sasuke and Sakura
- Anthropologie's 'Very Cute' Bow Stoneware Platter 'Adds a Romantic Touch to the Tablescape' for Just $32